Sublingual L-GSH Supplementation in Male Subjects With Smoking Habit and/or Hypertension

The strategies to prevent cardiovascular diseases play a prominent role in the guidelines of different scientific societies. Risk factors lead to several biological reactions within the cell in terms of pathophysiology, and thus of response to the homeostasis alteration. It is known that both smoking habit and hypertension alters endothelial functions through direct oxidative damage to endothelial cells, decrease in nitric oxide availability, and affects the mobilization of endothelial progenitor cells from the bone marrow.

Several studies have identified this response in the activation of mechanism that prevent the formation of oxidizing species, detoxifying any dangerous products. The antioxidant systems are, thus, the main endogenous defense against free radicals, and glutathione seems to play an important role in this mechanism. Reduced glutathione (GSH), formed by cysteine, glycine and glutamate, enters into the detoxification processes of endogenous products, such as peroxides which are the final pathway of many reactions caused by cardiovascular risk factors. It also acts on the exogenous compounds, such as pollutants, heavy metals and some drugs.

Changes in GSH homeostasis have been implicated in the etiology and progression of several diseases. A reduced bioavailability of GSH has been associated with neurodegenerative diseases such as Parkinson's and Alzheimer's or with increased risk of cardiovascular events.

The imbalance in the GSH homeostasis and aminothiols redox state is also involved in mechanisms that cause both chronic obstructive pulmonary and lung diseases and cystic fibrosis. Low levels of GSH have been found in individuals with HIV and are associated to reduced patients survival.

On the basis of previous data, it is conceivable that supplementation of GSH, whose concentrations decrease merely with age, may improve the endogenous antioxidant defense and may contribute to decrease of oxidants tissue damage, a typical characteristic of many acute and chronic diseases.

Several authors studied the effect of GSH oral administration in acute and in medium-long term treatment in healthy volunteers or in patients affected by different diseases. Unfortunately, they did not find any beneficial effect in terms of oxidative stress reduction and/or disease improvement. GSH was also administered intravenous, intramuscular or intrabronchial without positive results.

The efficacy of GSH treatment seems to be closely related to the degree of its absorption and to the increase of its concentrations in plasma and cells. Preliminary data obtained at the Institute of Clinical Physiology Institute of Milan in a small sample of healthy volunteers have shown that sublingual administration (100 mg) of a new preparation of L-glutathione (OXITION, PH\&T S.r.l.) is able to increase over 4 h, plasma and erythrocyte GSH concentrations with an average of 70% compared to the endogenous physiological levels. This increase is not detectable after oral intake of the same molecule due to the gastrointestinal barrier. The primary objective of this study is to determine whether medium-term sublingual administration of reduced L-GSH for 4 weeks to male subjects with risk factor smoking habit and/or arterial hypertension results in improved endothelial function, as assessed by arterial FMD, when compared to placebo. A favourable response to study compound will result in a greater endothelium-dependent vasodilatory ability as assessed by the ratio between peak flow after reactive hyperaemia and basal flow. Secondary study objective is to determine differences between L-GSH supplementation and placebo in terms of oxidative stress markers.

Sixteen male healthy subjects will be randomized to sequential allocation to reduced L-GSH or placebo, according to the following inclusion criteria: age from 40 to 60 years, without any signs or symptoms of cardio-cerebro-vascular event at the enrolment, with smoking habit (>10 cigarette/die) and/or arterial hypertension (PAS≥140 mmHg and/or PAD≥90 mmHg or in anti-hypertensive treatment). Consenting subjects will be enrolled and sequentially assigned to study treatment following a double-blind, cross over, randomized and controlled experimental design (L-GSH versus placebo) with a 3-week wash-out period between the two treatments. Each intervention will last 4 weeks. Baseline evaluation includes interview for history and nutritional characterization, blood pressure and heart rate assessment, blood sampling for routine haematological analysis [serum fasting glucose (GLU), total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), triglycerides (TG), creatinine (CREA), urea, gamma-glutamyl-transpeptidase (GGT), aspartate-amino transferase (AST) alanine-amino transferase (ALT)], and specific biochemical determination of endogenous redox status (total and reduced plasma aminothiols, total and reduced blood glutathione by HPLC) and oxidative stress mediators [plasma nitrotyrosine (NT), plasma malondialdehyde (MDA) and plasma 8-hydroxy-2'-deoxyguanosine (8-OHdG) by ELISA Kits]. FMD will be measured by a non invasive plethysmographic method (Endo-PAT2000) based on the registration of pulsatile blood volume in the fingertips of both hands.

After baseline assessment, patients will be randomized through a computer based procedure to active treatment or placebo in a 1:1 ratio. Study drug will be dispensed. At the 4-week follow-up, vital signs assessment, blood sampling for routine and specific biochemical determination, and FMD test will be again performed.